Publications by authors named "J Stentoft"
Clinical research has not been able to establish whether the differences between first- and second-generation BCR-ABL 1 kinase inhibitors are clinically relevant with regard to outcome. In the study by Alcazer et al., a relevant difference seems to emerge-paradoxically in the absence of the drugs-as demonstrated by differences in the relapse kinetics after cessation of therapy.
View Article and Find Full Text PDFArticle Synopsis
- * The DAstop2 study examined patients who previously failed a treatment-free remission (TFR) attempt, re-treating them with dasatinib for two years and assessing their ability to stop TKIs again.
- * Results showed that 61%, 56%, and 46% of patients maintained TFR at 6, 12, and 24 months after attempting a second stop, demonstrating that this approach is safe and effective for many patients.
Background: Patients with myeloproliferative neoplasms (MPNs) suffer from substantial symptoms and risk of debilitating complications, yet observational data on their labor market affiliation are scarce.
Material And Methods: We conducted a descriptive cohort study using data from Danish nationwide registries, including patients diagnosed with MPN in 2010-2016. Each patient was matched with up to ten comparators without MPN on age, sex, level of education, and region of residence.